GLP-1 Evidence

Pipeline

Oral GLP-1 pills: semaglutide 25 mg and orforglipron

The needle was never the main barrier, but removing it still matters. The oral agents work; they work slightly less well.

Updated 2 min read 7 citations Evidence strength 4/5

Two different bets

Oral semaglutide is the same peptide as the injection, formulated with an absorption enhancer to survive the stomach. It works, but peptide absorption is inefficient and variable, which is why the oral dose is enormous relative to the injected one and why it comes with instructions about water volume and fasting.

Orforglipron is a different proposition: a non-peptide small molecule that binds the same receptor [3]. It can be manufactured with conventional pharmaceutical chemistry, taken with or without food, and scaled the way ordinary pills are scaled.

What the trials found

OASIS 1 tested oral semaglutide 50 mg daily in adults with overweight or obesity and produced weight loss approaching the injectable result [5]. A subsequent trial at 25 mg reported in NEJM [2]. Orforglipron has now reported in both obesity [3] and early type 2 diabetes.

Oral agents in context
AgentTypeRouteBroad efficacy position
Semaglutide 2.4 mg [6]PeptideWeekly injectionReference standard, ≈15%
Oral semaglutide 50 mg [5]PeptideDaily tablet, fastedApproaches injectable
Oral semaglutide 25 mg [2]PeptideDaily tablet, fastedBelow the 50 mg result
Orforglipron [3]Small moleculeDaily tablet, any timeMeaningful, below injectable tirzepatide

Oral agent efficacy

Why manufacturing is the real story

The binding constraint on this drug class has been supply, not demand or efficacy. Peptides require specialised synthesis and sterile fill-finish capacity, which is why shortages persisted for years. A small molecule that can be pressed into tablets sidesteps that entirely.

For European health systems, that is the difference between a drug rationed to the highest-risk patients and one that can be prescribed at population scale. Efficacy differences of a few percentage points matter far less than whether the medicine exists in sufficient quantity.

What does not change

Everything downstream of the mechanism is the same. Gastrointestinal side effects behave the same way and are managed with the same gradual escalation — see side effects. Body-composition changes follow the same pattern — see muscle loss. And crucially, the withdrawal problem is unchanged: SELECT-era data confirms weight loss is maintained on treatment [4], and the STEP 1 extension confirms what happens off it [7]. A pill is still a chronic treatment.

Common questions

Is a pill as good as an injection?
Close but not equal on current data. Oral semaglutide approaches the injectable [5], and orforglipron is meaningful but below injectable tirzepatide [3].
Do I still need to escalate the dose?
Yes. The gastrointestinal effects are driven by the same mechanism, so the same gradual titration applies.
Are the oral versions cheaper?
Small molecules are fundamentally cheaper to make than peptides. Whether that reaches the patient depends on pricing and reimbursement rather than chemistry.
Will these replace injections?
For many people, probably. For maximum efficacy, injectable tirzepatide currently remains ahead — see tirzepatide.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Emerging pharmacotherapies for obesity: A systematic review Kokkorakis M, Chakhtoura M, Rhayem C, et al. · Pharmacological reviews · 2025 · Systematic review DOIPubMed 39952695
  2. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity Wharton S, Lingvay I, Bogdanski P, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40934115
  3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment Wharton S, Aronne LJ, Stefanski A, et al. · The New England journal of medicine · 2025 · Randomised controlled trial DOIPubMed 40960239
  4. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024 · Randomised controlled trial DOIPubMed 38740993Full text
  5. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Knop FK, Aroda VR, do Vale RD, et al. · Lancet (London, England) · 2023 · Randomised controlled trial DOIPubMed 37385278
  6. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. · The New England journal of medicine · 2023 · Randomised controlled trial DOIPubMed 37952131
  7. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Wilding JPH, Batterham RL, Davies M, et al. · Diabetes, obesity & metabolism · 2022 · Randomised controlled trial DOIPubMed 35441470Full text